Literature DB >> 12441674

Efficacy of purified Vi polysaccharide typhoid vaccine.

Jong-Hwan Park1, Jung-Joo Hong, Eun-Sil Choi, Jin-Won Lee, Jae-Hak Park.   

Abstract

This experiment was conducted to assess the efficacy of typhoid vaccine newly produced by purifying Vi antigen of Salmonella typhi. With Karber method, LD50 of challenging organism (S. typhi ty2) was determined as 6.31 CFU/mouse, and then the organism was used for the study. With Probits method, ED50 of the vaccine was determined as 0.016 microg / 0.5 ml / mouse. The ELISA titer (0.5097+/-0.0606) was 4 times in the group treated with high dose (0.25 microg/0.5ml) as in control (0.1113+/-0.0110). Six major protein bands of 66, 55, 35, 33, 18, and 9 kd were detected in Western blot analysis with serum of a vaccine treated mouse, whereas only one weak band of about 35 kd was detected with serum of a control mouse. We concluded that typhoid vaccine produced by purifying Vi antigen of S. typhi very effectively prevent S. typhi infection in mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441674

Source DB:  PubMed          Journal:  J Vet Sci        ISSN: 1229-845X            Impact factor:   1.672


  1 in total

1.  Development of a synthetic Vi polysaccharide vaccine for typhoid fever.

Authors:  Yawei Ni; Michael J Springer; Jianhua Guo; Isaac Finger-Baker; James P Wilson; Ronald R Cobb; Debra Turner; Ian Tizard
Journal:  Vaccine       Date:  2017-11-14       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.